TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fitness Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the system to detect Near Falls
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in atherosclerotic plaque burden and noncalcified plaque composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in coronary plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in angina score assessed by the Seattle Angina Questionnaire (SAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Penetration of fimepinostat across the blood brain barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency, relatedness, severity and duration of treatment emergent and treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of first cycle dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of medicines prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Genome-wide expression patterns of RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validation of results of the genome-wide analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteomic profiling of tumor and normal brainstem tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in performance at the Timed Up and Go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombin time assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in VES-13 score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of subjects achieving a serum neutralizing antibody titer >= 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects achieving a serum hemagglutination inhibition (HAI) antibody titer >= 40
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titer (GMT) of neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average Area Under the Curve (AUC) of MDASI Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude and satisfaction with video consultation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence rate of laboratory-confirmed STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of death after discharge
Endpoint domain: Mortality/survival
Primary endpoint: Changes of ultrasonographic optic nerve sheath diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in K-TEA Reading Comprehension Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate (ORR) by Independent Central Review (ICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic Adverse Events Following V114 or Prevnar 13™
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Vaccine-related Serious Adverse Events Following V114 or Prevnar 13™
Endpoint domain: Adverse events/effects
Primary endpoint: Time Until Analgesic Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood TSH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peripheral blood fT3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peripheral blood fT4 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Immunity duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lung bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Patient Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in cortical oxygenated hemoglobin (HbO2) signal during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cortical power spectral densities during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in body weight (weight loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leptin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMI (kg/m²) at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With the Detectable HCV RNA Results in Resistance Monitoring Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HCV RNA Levels in Resistance Monitoring Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Received Anti-HCV Medications in Resistance Monitoring Arm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Moods and Feelings Questionnaire (MFQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of occurrence of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients requiring Mechanical Ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of diffuse interstitial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of functional consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mortality in NICU
Endpoint domain: Mortality/survival
Primary endpoint: Change in gross motor function - sitting domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in segmental trunk control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in upper limb functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Interference as Measured by the Brief Pain Inventory (BPI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in Pain Interference as Measured by the Brief Pain Inventory (BPI) at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in Pain Interference as Measured by the Brief Pain Inventory (BPI) at Week 24
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of diaphragmatic paresis or paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fecal Fat Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surface current during defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in wound area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of cases with conclusive pleural workup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicities (DLT) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Who Successfully Improved Functional Level of Walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: response rate after one application of DepoCyte®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Event-free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline parenting self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline child's emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blastocyst percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of participants with clinically significant abnormal findings in hematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with clinically significant abnormal findings in clinical chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Off Time During Waking Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall GO outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Stratified by Acute Graft Versus Host Disease GVHD Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of mental health symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Procedural Side Branch Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero to infinity [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical survival of restoration, splint or retainer
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change in Hepatic Fat Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful heart transplants
Endpoint domain: Mortality/survival
Primary endpoint: Full Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: u-osm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relief of Knee Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: investigator assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of the ROC curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Anastomosis duration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Velocity of Displacement of Hyoid Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint angle during step descent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps muscle isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voluntary activation level of quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps muscle isometric endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety from bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration-Time (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of CMV Seropositive Subjects With Appearance or Increase of Anti-CMV Tegument Protein IgG Antibodies in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-CMV Tegument Protein IgG Antibody Concentration in Serum (ELISA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean CMVpp65 Antibody Concentration in Subjects Based on Number of CMV DNA Copies (pp65 Gene) in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electromyographic signals of the masseter and temporalis muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of treatment related dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Type and frequency of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Type and frequency of serious adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distal Contractile Integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global Hemostatic Efficacy Assessment Score (GHEA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triceps Skinfold Thickness (TSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAMC (Mid arm muscle circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prealbumin and albumin serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or first non-planned hospitalisation for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Duration of treatment with norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in verrucae diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of participants with an IGS score = 0 on target verruca
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of participants with an IGS score = 0 on at least 1 non-target verruca
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Maximum concentration of drug in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt (Area Under the Curve from the dosing time to the last measurable concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilatory adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Patient Health Questionnaire-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opioid antagonist rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percent Change From Baseline in Neuropsychological Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Qualitative foot assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin assessment of the foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ankle Brachial Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neuropsychiatric Inventory (NPI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to distant recurrence diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Central Arterial Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow-Mediated Dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Validity of CT-on-rails software
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Osteocalcin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child Emergency Room Presentation Rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mother Emergency Room Presentation Rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Child Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mother Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Everyday cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: changes in the Hamilton Depression Scale (HAMD-17) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: changes in the Montgomery-Asberg Depression Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum postoperative flexion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in HBV-DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing grade 4 or 5 study drug related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative score of HVLT-R, TMT A&B and COWA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three meter backward walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of tumor antigens that induce a humoral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Identification of tumor-secreted proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potential markers for early detection of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in self-management adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor skills development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory muscle morphology and functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Basal cerebral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Left Ventricle Global Longitudinal Strain (LV-GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Colorectal cancer screening uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful manufacture of UCD19 CAR T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants successfully infused with UCD19 CAR T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience a Dose Limiting Toxicity (DLT) within 30 days after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial function of the large vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time taken for intubation (TTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Respiratory degradation events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in knowledge about epilepsy disease
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in anxiety about epilepsy disease
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: System and Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion Efficacy of Low Energy VT Therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype frequency of SNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetic profile of pacritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically significant changes in Vital signs (blood pressure [BP], pulse rate [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in ADAS-Cog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Arterial Blood Gas (ABG) analysis-pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Blood Gas (ABG) analysis-Partial pressure of carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Blood Gas (ABG) analysis-Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes